# OnCo record pertuzumab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pertuzumab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pertuzumab" ;
  schema:name "Pertuzumab"@en ;
  schema:description "A second HER2 antibody that binds a different spot from trastuzumab, blocking HER2 from pairing with HER3; together they extended survival by 16 months in CLEOPATRA."@en ;
  schema:url <https://onco.cc/drugs/pertuzumab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pertuzumab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q1998021> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pertuzumab> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-HER2, dimerisation domain)" ;
  schema:alternateName "Perjeta; Phesgo (with trastuzumab, subcutaneous)" ;
  onco:approval "US 2012: First-line HER2+ metastatic breast cancer with trastuzumab and docetaxel", "US 2013: Neoadjuvant HER2+ early breast cancer (accelerated; first pCR-based approval)", "US 2017: Adjuvant HER2+ early breast cancer at high risk of recurrence", "US 2020: Phesgo subcutaneous fixed-dose combination with trastuzumab" ;
  onco:acceleratedApproval "US 2013-09-30: In combination with trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early early breast cancer" ;
  onco:acceleratedApprovalConfirmed "US 2017-12-20: In combination with trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early early breast cancer" ;
  onco:related <https://onco.cc/biomarkers/her2-ish-amplified/> ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/biliary-tract-cancer/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/her3/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:trials <https://onco.cc/trials/cleopatra/>, <https://onco.cc/trials/aphinity/>, <https://onco.cc/trials/destiny-breast09/>, <https://onco.cc/trials/her2climb-05/>, <https://onco.cc/trials/phergain/>, <https://onco.cc/trials/nct07518173/>, <https://onco.cc/trials/nct07196774/>, <https://onco.cc/trials/nct06891833/>, <https://onco.cc/trials/nct05593094/>, <https://onco.cc/trials/nct06445400/>, <https://onco.cc/trials/nct07102381/>, <https://onco.cc/trials/nct05802225/>, <https://onco.cc/trials/nct07294508/>, <https://onco.cc/trials/nct06057610/>, <https://onco.cc/trials/nct04208178/>, <https://onco.cc/trials/nct06771622/>, <https://onco.cc/trials/nct04538742/>, <https://onco.cc/trials/nct06178159/>, <https://onco.cc/trials/nct00781612/>, <https://onco.cc/trials/nct06686394/>, <https://onco.cc/trials/nct02320435/>, <https://onco.cc/trials/nct05150691/>, <https://onco.cc/trials/nct07140393/>, <https://onco.cc/trials/nct04514419/>, <https://onco.cc/trials/mypathway/>, <https://onco.cc/trials/determine-arm04/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/>, <https://onco.cc/key-papers/paper-javle-mypathway-her2-biliary-lancet-oncol-2021/> .